- Home
- LUCD vs RAPT Comparison
LUCD vs RAPT Comparison
Compare LUCD & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- RAPT
- Stock Information
- Founded
- LUCD 2018
- RAPT 2015
- Country
- LUCD United States
- RAPT United States
- Employees
- LUCD N/A
- RAPT N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- RAPT Health Care
- Exchange
- LUCD Nasdaq
- RAPT Nasdaq
- Market Cap
- LUCD 51.6M
- RAPT 59.1M
- IPO Year
- LUCD 2021
- RAPT 2019
- Fundamental
- Price
- LUCD $0.92
- RAPT $1.14
- Analyst Decision
- LUCD Strong Buy
- RAPT Hold
- Analyst Count
- LUCD 4
- RAPT 10
- Target Price
- LUCD $3.63
- RAPT $6.00
- AVG Volume (30 Days)
- LUCD 227.6K
- RAPT 1.5M
- Earning Date
- LUCD 03-24-2025
- RAPT 03-06-2025
- Dividend Yield
- LUCD N/A
- RAPT N/A
- EPS Growth
- LUCD N/A
- RAPT N/A
- EPS
- LUCD N/A
- RAPT N/A
- Revenue
- LUCD $4,189,000.00
- RAPT N/A
- Revenue This Year
- LUCD $91.72
- RAPT N/A
- Revenue Next Year
- LUCD $139.38
- RAPT N/A
- P/E Ratio
- LUCD N/A
- RAPT N/A
- Revenue Growth
- LUCD 179.27
- RAPT N/A
- 52 Week Low
- LUCD $0.63
- RAPT $0.79
- 52 Week High
- LUCD $1.50
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- LUCD 57.51
- RAPT 41.53
- Support Level
- LUCD $0.81
- RAPT $1.12
- Resistance Level
- LUCD $0.92
- RAPT $1.25
- Average True Range (ATR)
- LUCD 0.04
- RAPT 0.11
- MACD
- LUCD 0.01
- RAPT -0.02
- Stochastic Oscillator
- LUCD 78.26
- RAPT 20.00
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.